Clinical data demonstrate that elevated serum SRGN levels independently correlate with diminished overall survival and accelerated HCC recurrence, and corresponding immunohistochemical analysis revealed SRGN upregulation in 56.7% of HCC patients' specimens, contrasting sharply with minimal expression observed in only 3.1% of paired non-cancerous tissues31. Here, SRGN is linked to hepatocellular carcinoma.